Gold bars to be exempt from tariffs, White House clarifies
Cathie Wood’s ARK ETFs published their daily trades for Friday, January 31st, 2025, with a notable emphasis on the biotech sector. Leading the charge in purchases was CRISPR Therapeutics AG (NASDAQ:CRSP), with ARK buying a substantial 292,215 shares across its ARKK and ARKG ETFs, totaling $12,284,718 in value. This significant investment underscores ARK’s continued confidence in the gene-editing company.
On the sell side, ARK divested a total of 307,632 shares of Accolade Inc (NASDAQ:ACCD) from its ARKG ETF, amounting to $2,116,508. This follows a trend from the previous week, where ARK consistently reduced its position in Accolade.
Another major sale involved Roblox Corp (NYSE:RBLX), with 46,459 shares sold through the ARKK ETF, valued at $3,316,243. The sale represents a continuation of ARK’s gradual exit from the online gaming platform, as seen in previous days’ trades.
ARK also parted with 374,904 shares of Archer Aviation Inc (NYSE:ACHR) for $3,475,360, and 5,600 shares of Adyen (AS:ADYEN) NV (OTC:ADYEY) for $91,168, both through the ARKK ETF. Additionally, they sold 2,671 shares of AeroVironment Inc (NASDAQ:AVAV) through the ARKX (NYSE:ARKX) ETF, totaling $459,358, and a minor sale of 300 shares of Nu Holdings Ltd (NYSE:NU) for $4,031 from its ARKW ETF.
Conversely, ARK showed a growing interest in 10X Genomics Inc (NASDAQ:TXG), acquiring a total of 74,532 shares split between ARKK and ARKG ETFs, with a combined value of $1,123,942. This purchase aligns with ARK’s pattern of increasing its stake in the biotech company over the past week.
The daily trade report reflects ARK’s strategic adjustments in its ETF portfolios, highlighting the fund’s focus on innovative and disruptive companies while also taking profits and cutting positions in others. Investors keeping track of ARK’s movements may find these trends indicative of the fund’s broader investment thesis and market outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.